Oral administration of Lactococcus lactis-expressing heat shock protein 65 and tandemly repeated IA2P2 prevents type 1 diabetes in NOD mice

2016 ◽  
Vol 174 ◽  
pp. 28-36 ◽  
Author(s):  
Kun-Feng Liu ◽  
Xiao-Rui Liu ◽  
Guo-Liang Li ◽  
Shi-Ping Lu ◽  
Liang Jin ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Oral Administration ◽  
Lactococcus Lactis ◽  
Nod Mice ◽  
Heat Shock Protein 65

Antibodies to Heat-Shock Protein 65 and Neopterin Levels in Patients with Type 1 Diabetes Mellitus

2003 ◽  
Vol 111 (03) ◽  
pp. 127-131 ◽  
Author(s):  
R. Weitgasser ◽  
M. Lechleitner ◽  
T. Koch ◽  
G. Galvan ◽  
J. Mühlmann ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Type 1 Diabetes Mellitus ◽  
Heat Shock Protein 65

Antibodies to Heat Shock Protein 65 kD in Type 1 Diabetes Mellitus

1994 ◽  
Vol 11 (1) ◽  
pp. 66-70 ◽  
Author(s):  
R.Y.M. Tun ◽  
M.D. Smith ◽  
S.S.S. Lo ◽  
G.A.W. Rook ◽  
P. Lydyard ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Type 1 Diabetes Mellitus ◽  
Heat Shock Protein 65

scholarly journals A rationally designed peptide IA-2-P2 against type 1 diabetes in streptozotocin-induced diabetic mice

2017 ◽  
Vol 14 (3) ◽  
pp. 184-190 ◽  
Author(s):  
Lili Shen ◽  
Shiping Lu ◽  
Dongcheng Huang ◽  
Guoliang Li ◽  
Kunfeng Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Type 1 Diabetes Mellitus ◽  
Rabbit Model ◽  
Immunological Tolerance ◽  
Heat Shock Protein 60 ◽  
P2 Peptide

Recent studies have investigated the potential of type 1 diabetes mellitus–related autoantigens, such as heat shock protein 60, to induce immunological tolerance or to suppress the immune response. A functional 24-residue peptide derived from heat shock protein 60 (P277) has shown anti-type 1 diabetes mellitus potential in experimental animals and in clinical studies, but it also carries a potential atherogenic effect. In this study, we have modified P277 to retain an anti-type 1 diabetes mellitus effect and minimize the atherogenic potential by replacing the P277 B epitope with another diabetes-associated autoantigen, insulinoma antigen-2 (IA-2), to create the fusion peptide IA-2-P2. In streptozotocin-induced diabetic C57BL/6J mice, the IA-2-P2 peptide displayed similar anti-diabetic effects to the control P277 peptide. Also, the IA-2-P2 peptide did not show atherogenic activity in a rabbit model. Our findings indicate the potential of IA-2-P2 as a promising vaccine against type 1 diabetes mellitus.

β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

The Lancet ◽  
2001 ◽  
Vol 358 (9295) ◽  
pp. 1749-1753 ◽  
Author(s):  
Itamar Raz ◽  
Dana Elias ◽  
Ann Avron ◽  
Merana Tamir ◽  
Muriel Metzger ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Cell Function ◽  
Phase Ii Trial ◽  
Β Cell ◽  
Double Blind ◽  
Β Cell Function ◽  
New Onset

Oral delivery of staphylococcal nuclease by Lactococcus lactis prevents type 1 diabetes mellitus in NOD mice

2017 ◽  
Vol 101 (20) ◽  
pp. 7653-7662 ◽  
Author(s):  
Junchao Lang ◽  
Xiaoke Wang ◽  
Kunfeng Liu ◽  
Dongmei He ◽  
Pancong Niu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Lactococcus Lactis ◽  
Oral Delivery ◽  
Nod Mice ◽  
Staphylococcal Nuclease
Sign in / Sign up

Export Citation Format

Share Document